S
SalioGen Therapeutics
Advances in genetic therapies using its Exact DNA Integration Technology platform, a mammal-derived genome engineering technology
About SalioGen Therapeutics
SalioGen is a pioneering biotech startup that operates in the field of genetic medicine. The company's primary focus is on the development of a new category of genetic medicine, which they have termed "Gene Coding". This innovative approach involves the addition of a new genomic code to existing genes, allowing them to be turned on, off, or modified in their function. This is achieved through their proprietary Exact DNA Integration Technology (EDIT) platform, which uses unique mammal-derived enzymes known as Saliogase.
Read full description
The company's business model revolves around the development and commercialization of potentially curative therapies. Their initial focus is on creating durable, safe, and accessible genetic medicine for patients with inherited disorders. However, they plan to expand their platform's capabilities to include cell therapy, cell engineering, and biologics manufacturing. This expansion will allow them to serve a broader population of patients in need.
SalioGen's revenue is likely to come from the sale of their genetic therapies once they have been approved for use. They may also generate income from partnerships with other biotech companies or pharmaceutical firms interested in their technology.
In terms of their market, SalioGen operates in the rapidly growing field of genetic medicine. This market is driven by the increasing prevalence of genetic disorders and the ongoing advancements in genetic research and technology.
In summary, SalioGen is a biotech startup that is leveraging its proprietary technology to develop a new category of genetic medicine. Their goal is to transform the treatment paradigm for inherited disorders and beyond, ultimately improving the lives of patients.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Burlington, United States
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 61.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Rumoured $1B, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning SalioGen Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2022 | $115M | $460M | D1 Capital Partners · GordonMD Global Investment · Fidelity Investments · Cystic Fibrosis Foundation | ↗ |
| EARLY VCOther financing | Dec 2021 | $74M | $296M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for SalioGen Therapeutics is 340 monthly website visits, up 25.9% over the last three months. SalioGen Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
- PGPBM Capital Group
GordonMD Global Investment
EPIQ Capital Group
D1 Capital Partners
Fidelity Investments
Cystic Fibrosis Foundation
T. Rowe Price
Retinal Degeneration Fund
Symbiosis
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about SalioGen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SalioGen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.